171 related articles for article (PubMed ID: 21438791)
41. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma.
Lok T; Chen L; Lin F; Wang HL
Hum Pathol; 2014 Feb; 45(2):394-400. PubMed ID: 24439226
[TBL] [Abstract][Full Text] [Related]
42. Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior.
Yonezawa S; Goto M; Yamada N; Higashi M; Nomoto M
Proteomics; 2008 Aug; 8(16):3329-41. PubMed ID: 18651706
[TBL] [Abstract][Full Text] [Related]
43. Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation.
Pinto R; Carvalho AS; Conze T; Magalhães A; Picco G; Burchell JM; Taylor-Papadimitriou J; Reis CA; Almeida R; Mandel U; Clausen H; Söderberg O; David L
J Cell Mol Med; 2012 Jul; 16(7):1474-84. PubMed ID: 21883895
[TBL] [Abstract][Full Text] [Related]
44. Prognostic significance of muc4 expression in gallbladder carcinoma.
Lee HK; Cho MS; Kim TH
World J Surg Oncol; 2012 Oct; 10():224. PubMed ID: 23101681
[TBL] [Abstract][Full Text] [Related]
45. Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas.
Manne U; Weiss HL; Grizzle WE
Clin Cancer Res; 2000 Oct; 6(10):4017-25. PubMed ID: 11051251
[TBL] [Abstract][Full Text] [Related]
46. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
[TBL] [Abstract][Full Text] [Related]
47. Immunohistochemical study of the association between the progression of pancreatic ductal lesions and the expression of MUC1, MUC2, MUC5AC, and E-cadherin.
Kigure S
Rinsho Byori; 2006 May; 54(5):447-52. PubMed ID: 16789413
[TBL] [Abstract][Full Text] [Related]
48. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions.
Terris B; Dubois S; Buisine MP; Sauvanet A; Ruszniewski P; Aubert JP; Porchet N; Couvelard A; Degott C; Fléjou JF
J Pathol; 2002 Aug; 197(5):632-7. PubMed ID: 12210083
[TBL] [Abstract][Full Text] [Related]
49. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma.
Baldus SE; Mönig SP; Hanisch FG; Zirbes TK; Flucke U; Oelert S; Zilkens G; Madejczik B; Thiele J; Schneider PM; Hölscher AH; Dienes HP
Histopathology; 2002 May; 40(5):440-9. PubMed ID: 12010364
[TBL] [Abstract][Full Text] [Related]
50. Differentiation and prognostic markers in ampullary cancer: Role of p53, MDM2, CDX2, mucins and cytokeratins.
Perysinakis I; Minaidou E; Mantas D; Sotiropoulos GC; Leontara V; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Pathol Res Pract; 2016 Nov; 212(11):1039-1047. PubMed ID: 27688085
[TBL] [Abstract][Full Text] [Related]
51. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope.
Baldus SE; Wienand JR; Werner JP; Landsberg S; Drebber U; Hanisch FG; Dienes HP
Int J Oncol; 2005 Nov; 27(5):1289-97. PubMed ID: 16211224
[TBL] [Abstract][Full Text] [Related]
52. Immunoreactivity of Lewis blood group and mucin peptide core antigens: correlations with grade of dysplasia and malignant transformation in the colorectal adenoma-carcinoma sequence.
Baldus SE; Hanisch FG; Pütz C; Flucke U; Mönig SP; Schneider PM; Thiele J; Hölscher AH; Dienes HP
Histol Histopathol; 2002 Jan; 17(1):191-8. PubMed ID: 11813869
[TBL] [Abstract][Full Text] [Related]
53. Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors.
Yamasaki H; Ikeda S; Okajima M; Miura Y; Asahara T; Kohno N; Shimamoto F
Int J Oncol; 2004 Jan; 24(1):107-13. PubMed ID: 14654947
[TBL] [Abstract][Full Text] [Related]
54. Comparison between mucinous cystic neoplasm and intraductal papillary mucinous neoplasm of the branch duct type of the pancreas with respect to expression of CD10 and cytokeratin 20.
Nishigami T; Onodera M; Torii I; Sato A; Tao LH; Kushima R; Kakuno A; Kishimoto M; Katsuyama E; Fujimori T; Hirano H; Satake M; Kuroda N; Nishiguchi S; Fujimoto J; Tsujimura T
Pancreas; 2009 Jul; 38(5):558-64. PubMed ID: 19287335
[TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical expression profiles of MUC1 and MUC2 mucins in urothelial tumors of bladder.
Gonul II; Cakir A; Sozen S
Indian J Pathol Microbiol; 2018; 61(3):350-355. PubMed ID: 30004053
[TBL] [Abstract][Full Text] [Related]
56. Claudin-18 as a Marker for Identifying the Stomach and Pancreatobiliary Tract as the Primary Sites of Metastatic Adenocarcinoma.
Li WT; Jeng YM; Yang CY
Am J Surg Pathol; 2020 Dec; 44(12):1643-1648. PubMed ID: 32925194
[TBL] [Abstract][Full Text] [Related]
57. Heterogeneity of mucin gene expression in normal and neoplastic tissues.
Ho SB; Niehans GA; Lyftogt C; Yan PS; Cherwitz DL; Gum ET; Dahiya R; Kim YS
Cancer Res; 1993 Feb; 53(3):641-51. PubMed ID: 7678777
[TBL] [Abstract][Full Text] [Related]
58. Expression of MUC1 and MUC2 in ampullary cancer.
Moriya T; Kimura W; Hirai I; Takasu N; Mizutani M
Int J Surg Pathol; 2011 Aug; 19(4):441-7. PubMed ID: 21700631
[TBL] [Abstract][Full Text] [Related]
59. MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance.
Betge J; Schneider NI; Harbaum L; Pollheimer MJ; Lindtner RA; Kornprat P; Ebert MP; Langner C
Virchows Arch; 2016 Sep; 469(3):255-65. PubMed ID: 27298226
[TBL] [Abstract][Full Text] [Related]
60. MUC5B expression in gastric carcinoma: relationship with clinico-pathological parameters and with expression of mucins MUC1, MUC2, MUC5AC and MUC6.
Pinto-de-Sousa J; Reis CA; David L; Pimenta A; Cardoso-de-Oliveira M
Virchows Arch; 2004 Mar; 444(3):224-30. PubMed ID: 14758553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
